ARTES successfully completed EU funded project Plurivax

ARTES Biotech­nol­o­gy explored very effec­tive in a SME con­sor­tium vac­cine devel­op­ments for vet­eri­nary appli­ca­tions. Under the titel: “ERA-Net Euro­­­Tran­s­Bio-8: PLURIVAX, devel­op­ment of a virus-like-par­ti­­­cle (VLP) based vac­cine plat­form and sta­ble for­mu­la­tion espe­cial­ly suit­ed for the vet­eri­nary appli­ca­tions, the EU coop­er­a­tion was part of the 8th Euro­Trans­Bio call and was fund­ed in the time peri­od from […]

ARTES attends Bio-Europe Spring 2018

Meet us at the Bio-Europe Spring 2018 tak­ing place in Ams­ter­dam March 12 -14. Michael Pio­ntek, Man­ag­ing Direc­tor at ARTES, will be present in the One-on-One Part­ner­ing pre­sent­ing ARTES’ inno­v­a­tive range of cell line and process devel­op­ment solu­tions for bio-phar­­­ma­ceu­ti­­­cal and vac­cine prod­ucts. Con­tact us pre­vi­ous­ly for orga­niz­ing a per­son­al meet­ing or drop us a […]

ARTES brings new vaccine advances to veterinary ‘Dragons’ Den’

ARTES will attend February’s Euro­pean Ani­mal Health Invest­ment Forum in Lon­don and will present its inno­v­a­tive tech­nolo­gies to poten­tial part­ners This will be ARTES’ sec­ond par­tic­i­pa­tion in the high pres­tige invest­ment net­work­ing event, which is seen as the ‘Drag­ons’ Den’ of vet­eri­nary med­i­cine. ARTES Man­ag­ing Direc­tor, Dr. Michael Pio­ntek, will use the forum to talk […]